Retatrutide Phase 3: What the TRIUMPH-1 Results Show

Eli Lilly reported topline results from TRIUMPH-1, the pivotal Phase 3 obesity trial of retatrutide, in May 2026 ^[1]. The headline figures are the largest published for any pharmacological weight-reduction agent. They also arrive with the caveats that always attach to a sponsor announcement, and separating the two is the point of this piece.

What was tested

TRIUMPH-1 (NCT05929066) randomised 2,339 participants to once-weekly retatrutide at 4 mg, 9 mg or 12 mg, or placebo, over 80 weeks, with a pre-specified extension to 104 weeks.

Retatrutide is a triple agonist: it activates the GLP-1 receptor, the GIP receptor, and — unlike any approved drug in the class — the glucagon receptor. Glucagon receptor agonism raises energy expenditure and promotes hepatic fat oxidation, at the cost of raising blood glucose in isolation. The design premise is that concurrent incretin agonism offsets the glycaemic cost.

What was reported

| Arm | Mean weight reduction at 80 weeks | | --- | --- | | Retatrutide 4 mg | 19.0% (47.2 lb) | | Retatrutide 9 mg | 25.9% (64.4 lb) | | Retatrutide 12 mg | 28.3% (70.3 lb) | | Placebo | 2.2% (5.5 lb) |

In the extension to 104 weeks, the 12 mg group reached a mean reduction of 30.3% (85.0 lb), with 45.3% of participants achieving at least 30% weight reduction.

For context, the pivotal trials of tirzepatide reported mean reductions of roughly 16.0% to 22.5% at 72 weeks, and the published Phase 2 retatrutide data reported approximately 24% at 48 weeks ^[2].

What belongs next to those numbers

The tolerability figures. Common adverse events were nausea, diarrhoea, constipation and vomiting. Discontinuation due to adverse events was 4.1%, 6.9% and 11.3% for the 4 mg, 9 mg and 12 mg doses, against 4.9% for placebo. Roughly one in nine participants on the highest dose stopped because of side effects — a meaningful number that does not appear in most coverage of this result.

The source. These are sponsor-reported topline results. The full dataset has not been through peer review or regulatory scrutiny. That is normal at this stage and it is not an accusation; it is a statement about what has and has not yet been independently examined. Topline announcements have been revised on fuller analysis before.

What was measured. Body weight. TRIUMPH-1 was not designed to measure cardiovascular events, mortality, or any other hard clinical outcome. Semaglutide's cardiovascular indication rests on a dedicated 17,000-participant outcomes trial; retatrutide has no equivalent result yet.

What is not yet known. Effects on lean mass and bone at reductions of this magnitude. Durability after discontinuation. Long-term safety. Performance in populations excluded from the trial.

What has to happen next

Retatrutide remains investigational. Between a positive Phase 3 topline and a medicine sits peer-reviewed publication, submission of a complete application, FDA review of the raw data, and the drafting of a label with its contraindications, warnings and limitations of use.

Peptide Insider will update the retatrutide profile when the peer-reviewed publication appears and again if and when a regulatory decision is made.